Thyrocare Technologies
1,124.20
-75.30(-6.28%)
Market Cap₹5,957.60 Cr
PE Ratio55.86
Company Performance:
1D-6.28%
1M-11.26%
6M+56.75%
1Y+35.58%
5Y+47.05%
View Company Insightsright
More news about Thyrocare Technologies
06Aug 25
Thyrocare's Rahul Guha to Lead API Holdings as CEO While Retaining Current Role
Rahul Guha, current MD and CEO of Thyrocare Technologies, will additionally become MD and CEO of API Holdings from August 27, 2025. He will maintain his position at Thyrocare while taking on new responsibilities at API Holdings. Siddharth Shah, current MD and CEO of API Holdings, will be re-designated as Director and Vice Chairman. This move aims to enhance synergies between Thyrocare and its parent company, API Holdings.
30Jun 25
Thyrocare Technologies Faces ₹133.1 Crore Tax Demand
Thyrocare Technologies Ltd., a leading diagnostics and preventive healthcare service provider, has received two significant tax demands totaling ₹133.10 crore. The demands include ₹2.10 crore and ₹131.00 crore. The company's disclosure lacks specific details about the nature of these demands, the tax periods involved, or the grounds for the claims. This substantial tax liability could potentially impact Thyrocare's financial position, cash flow management, and future planning.
23Apr 25
Thyrocare Technologies Reports Strong Growth in Q4 and FY25, Achieves 100% NABL Accreditation
Thyrocare Technologies Limited announced robust financial results for Q4 and FY25. Q4 saw a 21% YoY revenue increase to INR 187.20 crore, with 78% EBITDA growth and 88% PAT surge. FY25 annual revenue rose 20% to INR 687.30 crore, with 37% EBITDA growth and 45% PAT increase. The company became India's first 100% NABL accredited national diagnostic lab chain, processed 167.9 million tests, and expanded its franchisee network. Strategic acquisitions of Polo Labs and Vimta Labs' diagnostic business were completed. The Board recommended a final dividend of INR 21.00 per share.
03Mar 25
Thyrocare Technologies Strengthens Tanzanian Joint Venture with $25,000 Investment
Thyrocare Technologies has invested an additional $25,000 (₹21.98 lakh) in its Tanzanian joint venture, Thyrocare Laboratories (Tanzania) Limited. This investment is part of a larger ₹15 crore plan. The joint venture, operational since April 2024, reported a turnover of ₹0.44 crore for the nine months ended December 31, 2024. With this investment, Thyrocare's stake temporarily exceeds 50%, potentially making the joint venture a subsidiary. The shareholding is expected to revert to 50:50 once partners contribute their equity portion.
Thyrocare Technologies
1,124.20
-75.30
(-6.28%)
1 Year Returns:+35.58%
Industry Peers
Dr. Lal Path Labs
3,194.50
(-2.04%)
Vijaya Diagnostic Centre
1,019.90
(-1.97%)
Metropolis Healthcare
2,014.60
(-0.58%)
Thyrocare Technologies
1,124.20
(-6.28%)
Krsnaa Diagnostics
793.35
(-2.35%)
Suraksha Diagnostic
298.00
(-3.99%)
3B BlackBio DX
1,364.00
(-1.33%)
Sastasundar Ventures
313.20
(+0.93%)
Choksi Laboratories
189.90
(-0.60%)